Innocan Pharma™ is a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations.
a highly experienced management team
with a proven track record
in the pharmaceutical industry.
INNOCAN Pharma™ COMPANY OVERVIEW
Cannabinoid-integrated enhanced formula with smart dermatology platform
Quality of life
Improved efficacy, administration and compliance
OUR FOCUS FOR RAPID GROWTH
- Relief of Psoriasis symptoms (topical treatments)
- Muscle Pain and Rheumatic Pain (topical treatment)
- Collaboration with Yissum Research Development, a commercial research arm of Hebrew University of Jerusalem
- Breakthrough platform for delivery of cannabinoids by controlled injection to specific internal body target.
R&D EXPERTISE for
- Best-in-class R&D/licensing team
- Experts in developing integrated products for various dermal applications
OUR FIRST-LINE PRODUCTS
INNOVATIVE, FAST-ACTING PAIN RELIEF CREAM
1.5 billion people worldwide are affected by pain, with 50% of doctors’ visits pain related!
We at Innocan Pharma™ want to help the millions of patients seeking better topical treatment options
Effect of Menthol & Methyl salicylate with CBD Hemp oil (Cannabinoid complex)
MULTI DISCIPLINARY MANAGEMENT TEAM WITH
Founder & Executive Chairman
Extensive experience in the pharmaceutical sector. Served as Teva CEO Israel & Africa, previously CEO of SLE and CEO Abic Pharma. He currently serves as Director & Chairman of a variety of public and private companies.
Founder VP BD
Successful Israeli entrepreneur and expert in the establishment of start-ups. Co-founded Pluristem (NASDAQ:PSTI), Brainstorm (NASDAQ:BCLI) and Cell Source Ltd. (CLCS.OB).
Founder & CEO
Vast experience and proven track record in developing global business strategies to open and penetrate new markets. Managed hundreds of successful international transactions from senior management positions (Kamedis, Efal). Accompanied startups from early stage to commercialization (Tagra).
Vast CFO experience for public and private companies. Served as the CFO of Pfizer Israel, Merck. Extensive experience in Biotech.
Accompanied fast-growing companies from early stage to the highly regulated arena of public companies.
Founder & CTO
Senior pharmaceutics scientist with more than 30 years of experience. Serves as VP R&D at Careline, a member of the pharmaceutical innovation team at Perrigo. He holds several patents in OTC (over-the-counter) applications.
HIGHLY EXPERIENCED Advisory Board
PROFESSOR CHEZY BARENHOLZ
Professor of Biochemistry and Head of the Department of Biochemistry at the Hebrew University of Jerusalem. He is on the Editorial Boards of Chemistry and Physics of Lipids and the Journal of Liposome Research. He is one of the key inventors of DOXIL, marketed by Johnson & Johnson as a cancer treatment. He has authored over 300 publications and holds over 30 patents.
Professor Michael David
Internationally recognized dermatologist and award-winning scientist. Head of the Dermatology Department, Rabin Medical Center, Israel. Authored and co-authored over 200 national and international publications. Worked as a reviewer for reputed professional journals
Dr. Stephen Cherkez
Served as head of Teva’s Chemical Research Division; founder of Chem-Agis and President of its chemistry division; and VP BD at Agis. Since 2003, he has held a double position at Perrigo as VP Intellectual Property and VP Product Development. He has filed and participated in the writing of 33 patent families.